ID   SIR2_HUMAN              Reviewed;         389 AA.
AC   Q8IXJ6; A8K3V1; B2RB45; O95889; Q924Y7; Q9P0G8; Q9UNT0; Q9Y6E9;
AC   U5TP13;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=NAD-dependent protein deacetylase sirtuin-2;
DE            EC=3.5.1.-;
DE   AltName: Full=Regulatory protein SIR2 homolog 2;
DE   AltName: Full=SIR2-like protein 2;
GN   Name=SIRT2; Synonyms=SIR2L, SIR2L2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF HIS-187.
RC   TISSUE=Testis;
RX   PubMed=10381378; DOI=10.1006/bbrc.1999.0897;
RA   Frye R.A.;
RT   "Characterization of five human cDNAs with homology to the yeast SIR2
RT   gene: Sir2-like proteins (sirtuins) metabolize NAD and may have
RT   protein ADP-ribosyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 260:273-279(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=10393250; DOI=10.1016/S0378-1119(99)00162-6;
RA   Afshar G., Murnane J.P.;
RT   "Characterization of a human gene with sequence homology to
RT   Saccharomyces cerevisiae SIR2.";
RL   Gene 234:161-168(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12065666; DOI=10.1046/j.1471-4159.2002.00847.x;
RA   De Smet C., Nishimori H., Furnari F.B., Boegler O., Huang H.-J.S.,
RA   Cavenee W.K.;
RT   "A novel seven transmembrane receptor induced during the early steps
RT   of astrocyte differentiation identified by differential expression.";
RL   J. Neurochem. 81:575-588(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2), FUNCTION IN DEACETYLATION (ISOFORMS 1 AND 2), LACK OF
RP   DEACETYLATION (ISOFORM 5), INTERACTION WITH EP300 (ISOFORMS 1; 2 AND
RP   5), AND SUBCELLULAR LOCATION (ISOFORMS 1; 2 AND 5).
RX   PubMed=24177535; DOI=10.1016/j.jmb.2013.10.027;
RA   Rack J.G., Vanlinden M.R., Lutter T., Aasland R., Ziegler M.;
RT   "Constitutive nuclear localization of an alternatively spliced
RT   sirtuin-2 isoform.";
RL   J. Mol. Biol. 426:1677-1691(2014).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Lennerz V., Fatho M., Gentilini C., Lifke A., Woelfel C., Woelfel T.;
RT   "Response of autologous T cells to a human melanoma is dominated by
RT   individual mutant antigens.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Adrenal gland;
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H.,
RA   Gu B.-W., Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J.,
RA   Xu S.-H., Gu J., Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M.,
RA   Huang G.-Y., Chen Z., Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal
RT   axis and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Lung;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 22-389 (ISOFORM 4).
RC   TISSUE=Brain;
RA   Mei G., Yu W., Gibbs R.A.;
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11226170; DOI=10.1093/emboj/20.1.197;
RA   Perrod S., Cockell M.M., Laroche T., Renauld H., Ducrest A.L.,
RA   Bonnard C., Gasser S.M.;
RT   "A cytosolic NAD-dependent deacetylase, Hst2p, can modulate nucleolar
RT   and telomeric silencing in yeast.";
RL   EMBO J. 20:197-209(2001).
RN   [12]
RP   INHIBITION BY SIRTINOL; A3 AND M15.
RX   PubMed=11483616; DOI=10.1074/jbc.M106779200;
RA   Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., Schreiber S.L.;
RT   "Identification of a class of small molecule inhibitors of the sirtuin
RT   family of NAD-dependent deacetylases by phenotypic screening.";
RL   J. Biol. Chem. 276:38837-38843(2001).
RN   [13]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-187.
RX   PubMed=11812793; DOI=10.1074/jbc.M111830200;
RA   Borra M.T., O'Neill F.J., Jackson M.D., Marshall B.L., Verdin E.,
RA   Foltz K.R., Denu J.M.;
RT   "Conserved enzymatic production and biological effect of O-acetyl-ADP-
RT   ribose by silent information regulator 2-like NAD+-dependent
RT   deacetylases.";
RL   J. Biol. Chem. 277:12632-12641(2002).
RN   [14]
RP   FUNCTION IN DEACETYLATION OF TUBULIN, SUBCELLULAR LOCATION,
RP   INTERACTION WITH HDAC6, AND MUTAGENESIS OF ASN-168 AND HIS-187.
RX   PubMed=12620231; DOI=10.1016/S1097-2765(03)00038-8;
RA   North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E.;
RT   "The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin
RT   deacetylase.";
RL   Mol. Cell 11:437-444(2003).
RN   [15]
RP   FUNCTION AS REGULATOR OF CELL CYCLE PROGRESSION, SUBCELLULAR LOCATION,
RP   DEVELOPMENTAL STAGE, PHOSPHORYLATION, UBIQUITINATION, AND MUTAGENESIS
RP   OF HIS-187.
RX   PubMed=12697818; DOI=10.1128/MCB.23.9.3173-3185.2003;
RA   Dryden S.C., Nahhas F.A., Nowak J.E., Goustin A.-S., Tainsky M.A.;
RT   "Role for human SIRT2 NAD-dependent deacetylase activity in control of
RT   mitotic exit in the cell cycle.";
RL   Mol. Cell. Biol. 23:3173-3185(2003).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=12963026; DOI=10.1016/j.bbrc.2003.08.029;
RA   Hiratsuka M., Inoue T., Toda T., Kimura N., Shirayoshi Y.,
RA   Kamitani H., Watanabe T., Ohama E., Tahimic C.G.T., Kurimasa A.,
RA   Oshimura M.;
RT   "Proteomics-based identification of differentially expressed genes in
RT   human gliomas: down-regulation of SIRT2 gene.";
RL   Biochem. Biophys. Res. Commun. 309:558-566(2003).
RN   [17]
RP   INTERACTION WITH HOXA10.
RX   PubMed=15213244; DOI=10.1093/jb/mvh084;
RA   Bae N.S., Swanson M.J., Vassilev A., Howard B.H.;
RT   "Human histone deacetylase SIRT2 interacts with the homeobox
RT   transcription factor HOXA10.";
RL   J. Biochem. 135:695-700(2004).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16079181; DOI=10.1091/mbc.E05-01-0033;
RA   Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I.;
RT   "Evolutionarily conserved and nonconserved cellular localizations and
RT   functions of human SIRT proteins.";
RL   Mol. Biol. Cell 16:4623-4635(2005).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [20]
RP   FUNCTION IN DEACETYLATION OF HISTONE H4 AND H3, CATALYTIC ACTIVITY,
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=16648462; DOI=10.1101/gad.1412706;
RA   Vaquero A., Scher M.B., Lee D.H., Sutton A., Cheng H.L., Alt F.W.,
RA   Serrano L., Sternglanz R., Reinberg D.;
RT   "SirT2 is a histone deacetylase with preference for histone H4 Lys 16
RT   during mitosis.";
RL   Genes Dev. 20:1256-1261(2006).
RN   [21]
RP   FUNCTION AS REGULATOR IN CELL CYCLE PROGRESSION, PHOSPHORYLATION AT
RP   SER-368 BY CDK1, DEPHOSPHORYLATION AT SER-368 BY CDC14A AND CDC14B,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF HIS-187 AND SER-368.
RX   PubMed=17488717; DOI=10.1074/jbc.M702990200;
RA   North B.J., Verdin E.;
RT   "Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent
RT   phosphorylation.";
RL   J. Biol. Chem. 282:19546-19555(2007).
RN   [22]
RP   INTERACTION WITH HDAC6 (ISOFORMS 1 AND 2), PHOSPHORYLATION AT SER-372
RP   AND SER-368, UBIQUITINATION, AND MUTAGENESIS OF SER-53; SER-98;
RP   SER-100; HIS-187; SER-279; THR-280; SER-311; TYR-315; SER-364; SER-368
RP   AND SER-372.
RX   PubMed=17516032; DOI=10.1007/s11010-007-9478-6;
RA   Nahhas F., Dryden S.C., Abrams J., Tainsky M.A.;
RT   "Mutations in SIRT2 deacetylase which regulate enzymatic activity but
RT   not its interaction with HDAC6 and tubulin.";
RL   Mol. Cell. Biochem. 303:221-230(2007).
RN   [23]
RP   FUNCTION IN AXONAL DEGENERATION.
RX   PubMed=17574768; DOI=10.1016/j.neuroscience.2007.04.059;
RA   Suzuki K., Koike T.;
RT   "Mammalian Sir2-related protein (SIRT) 2-mediated modulation of
RT   resistance to axonal degeneration in slow Wallerian degeneration mice:
RT   a crucial role of tubulin deacetylation.";
RL   Neuroscience 147:599-612(2007).
RN   [24]
RP   FUNCTION AS REGULATOR OF MITOTIC CELL CYCLE CHECKPOINT, SUBCELLULAR
RP   LOCATION, NUCLEOCYTOPLASMIC SHUTTLING, INDUCTION, TISSUE SPECIFICITY,
RP   AND MUTAGENESIS OF GLN-167; ASN-168 AND HIS-187.
RX   PubMed=16909107; DOI=10.1038/sj.onc.1209857;
RA   Inoue T., Hiratsuka M., Osaki M., Yamada H., Kishimoto I.,
RA   Yamaguchi S., Nakano S., Katoh M., Ito H., Oshimura M.;
RT   "SIRT2, a tubulin deacetylase, acts to block the entry to chromosome
RT   condensation in response to mitotic stress.";
RL   Oncogene 26:945-957(2007).
RN   [25]
RP   FUNCTION AS REGULATOR IN CELL CYCLE PROGRESSION, INTERACTION WITH
RP   AURKA, SUBCELLULAR LOCATION, NUCLEOCYTOPLASMIC SHUTTLING, AND
RP   MUTAGENESIS OF HIS-187.
RX   PubMed=17726514; DOI=10.1371/journal.pone.0000784;
RA   North B.J., Verdin E.;
RT   "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2
RT   during mitosis.";
RL   PLoS ONE 2:E784-E784(2007).
RN   [26]
RP   FUNCTION IN DEACETYLATION OF TP53, FUNCTION IN REGULATION OF TP53, AND
RP   INTERACTION WITH YWHAB AND YWHAG.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the
RT   activity of p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [27]
RP   INTERACTION WITH EP300, ACETYLATION BY EP300, AND ENZYME REGULATION.
RX   PubMed=18722353; DOI=10.1016/j.bbrc.2008.08.042;
RA   Han Y., Jin Y.H., Kim Y.J., Kang B.Y., Choi H.J., Kim D.W., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Acetylation of Sirt2 by p300 attenuates its deacetylase activity.";
RL   Biochem. Biophys. Res. Commun. 375:576-580(2008).
RN   [28]
RP   FUNCTION IN STRESS RESPONSE, AND INDUCTION BY STRESS.
RX   PubMed=18640115; DOI=10.1016/j.febslet.2008.07.016;
RA   Lynn E.G., McLeod C.J., Gordon J.P., Bao J., Sack M.N.;
RT   "SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via
RT   regulation of 14-3-3 zeta and BAD in H9c2 cells.";
RL   FEBS Lett. 582:2857-2862(2008).
RN   [29]
RP   FUNCTION IN DEACETYLATION OF ALPHA-TUBULIN AND HISTONE, FUNCTION IN
RP   REGULATION OF CELL MOTILITY, INTERACTION WITH CDK5R1; CDK5 AND CYCLIN
RP   E-CDK2 COMPLEX, PHOSPHORYLATION AT SER-368 BY CDK2 AND CDK5, AND
RP   MUTAGENESIS OF SER-368.
RX   PubMed=18332217; DOI=10.1083/jcb.200707126;
RA   Pandithage R., Lilischkis R., Harting K., Wolf A., Jedamzik B.,
RA   Luscher-Firzlaff J., Vervoorts J., Lasonder E., Kremmer E., Knoll B.,
RA   Luscher B.;
RT   "The regulation of SIRT2 function by cyclin-dependent kinases affects
RT   cell motility.";
RL   J. Cell Biol. 180:915-929(2008).
RN   [30]
RP   FUNCTION IN DEACETYLATION OF EP300 AND ALPHA-TUBULIN, FUNCTION IN
RP   REGULATION OF EP300, AND SUBCELLULAR LOCATION.
RX   PubMed=18995842; DOI=10.1016/j.molcel.2008.09.018;
RA   Black J.C., Mosley A., Kitada T., Washburn M., Carey M.;
RT   "The SIRT2 deacetylase regulates autoacetylation of p300.";
RL   Mol. Cell 32:449-455(2008).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [33]
RP   FUNCTION AS REGULATOR OF MITOTIC CELL CYCLE CHECKPOINT.
RX   PubMed=19282667; DOI=10.4161/cc.8.8.8245;
RA   Inoue T., Nakayama Y., Yamada H., Li Y.C., Yamaguchi S., Osaki M.,
RA   Kurimasa A., Hiratsuka M., Katoh M., Oshimura M.;
RT   "SIRT2 downregulation confers resistance to microtubule inhibitors by
RT   prolonging chronic mitotic arrest.";
RL   Cell Cycle 8:1279-1291(2009).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   FUNCTION IN DEACETYLATION OF HISTONE H3.
RX   PubMed=20587414; DOI=10.1074/jbc.M110.149393;
RA   Vempati R.K., Jayani R.S., Notani D., Sengupta A., Galande S.,
RA   Haldar D.;
RT   "p300-mediated acetylation of histone H3 lysine 56 functions in DNA
RT   damage response in mammals.";
RL   J. Biol. Chem. 285:28553-28564(2010).
RN   [36]
RP   FUNCTION IN DEACETYLATION OF RELA, FUNCTION IN REGULATION OF RELA
RP   ACTIVITY, INTERACTION WITH RELA, AND SUBCELLULAR LOCATION.
RX   PubMed=21081649; DOI=10.1242/jcs.073783;
RA   Rothgiesser K.M., Erener S., Waibel S., Luscher B., Hottiger M.O.;
RT   "SIRT2 regulates NF-kappaB dependent gene expression through
RT   deacetylation of p65 Lys310.";
RL   J. Cell Sci. 123:4251-4258(2010).
RN   [37]
RP   FUNCTION IN DEACETYLATION OF FOXO1, FUNCTION IN AUTOPHAGY, AND
RP   INTERACTION WITH FOXO1.
RX   PubMed=20543840; DOI=10.1038/ncb2069;
RA   Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., Wang D.,
RA   Feng J., Yu L., Zhu W.G.;
RT   "Cytosolic FoxO1 is essential for the induction of autophagy and
RT   tumour suppressor activity.";
RL   Nat. Cell Biol. 12:665-675(2010).
RN   [38]
RP   FUNCTION IN DEACETYLATION OF CDC20 AND FZR1, FUNCTION AS A TUMOR
RP   SUPPRESSOR, TISSUE SPECIFICITY, AND MUTAGENESIS OF HIS-187.
RX   PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004;
RA   Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X.,
RA   Li C., Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H.,
RA   Cha Y.I., Gius D., Deng C.X.;
RT   "SIRT2 maintains genome integrity and suppresses tumorigenesis through
RT   regulating APC/C activity.";
RL   Cancer Cell 20:487-499(2011).
RN   [39]
RP   TISSUE SPECIFICITY.
RX   PubMed=21791548; DOI=10.1093/hmg/ddr326;
RA   Maxwell M.M., Tomkinson E.M., Nobles J., Wizeman J.W., Amore A.M.,
RA   Quinti L., Chopra V., Hersch S.M., Kazantsev A.G.;
RT   "The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein
RT   that accumulates in the aging CNS.";
RL   Hum. Mol. Genet. 20:3986-3996(2011).
RN   [40]
RP   FUNCTION IN DEACETYLATION OF PCK1, POSSIBLE FUNCTION IN REGULATION OF
RP   BLOOD GLUCOSE HOMEOSTASIS, AND INDUCTION BY GLUCOSE.
RX   PubMed=21726808; DOI=10.1016/j.molcel.2011.04.028;
RA   Jiang W., Wang S., Xiao M., Lin Y., Zhou L., Lei Q., Xiong Y.,
RA   Guan K.L., Zhao S.;
RT   "Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation
RT   via recruiting the UBR5 ubiquitin ligase.";
RL   Mol. Cell 43:33-44(2011).
RN   [41]
RP   FUNCTION IN DEACETYLATION OF PARD3, AND INTERACTION WITH PARD3.
RX   PubMed=21949390; DOI=10.1073/pnas.1104969108;
RA   Beirowski B., Gustin J., Armour S.M., Yamamoto H., Viader A.,
RA   North B.J., Michan S., Baloh R.H., Golden J.P., Schmidt R.E.,
RA   Sinclair D.A., Auwerx J., Milbrandt J.;
RT   "Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through
RT   polarity protein Par-3/atypical protein kinase C (aPKC) signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:E952-961(2011).
RN   [42]
RP   FUNCTION IN DEACETYLATION OF EIF5A.
RX   PubMed=22771473; DOI=10.1016/j.febslet.2012.06.042;
RA   Ishfaq M., Maeta K., Maeda S., Natsume T., Ito A., Yoshida M.;
RT   "Acetylation regulates subcellular localization of eukaryotic
RT   translation initiation factor 5A (eIF5A).";
RL   FEBS Lett. 586:3236-3241(2012).
RN   [43]
RP   FUNCTION IN AUTOPHAGY, AND SUBCELLULAR LOCATION.
RX   PubMed=22819792; DOI=10.1016/j.neuint.2012.07.010;
RA   Gal J., Bang Y., Choi H.J.;
RT   "SIRT2 interferes with autophagy-mediated degradation of protein
RT   aggregates in neuronal cells under proteasome inhibition.";
RL   Neurochem. Int. 61:992-1000(2012).
RN   [44]
RP   REVIEW, AND FUNCTION AS A TUMOR SUPPRESSOR.
RX   PubMed=22943040;
RA   Park S.H., Zhu Y., Ozden O., Kim H.S., Jiang H., Deng C.X., Gius D.,
RA   Vassilopoulos A.;
RT   "SIRT2 is a tumor suppressor that connects aging, acetylome, cell
RT   cycle signaling, and carcinogenesis.";
RL   Transl. Cancer Res. 1:15-21(2012).
RN   [45]
RP   INTERACTION WITH MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=23806683; DOI=10.1016/j.bbrc.2013.06.053;
RA   Choi Y.H., Kim H., Lee S.H., Jin Y.H., Lee K.Y.;
RT   "ERK1/2 regulates SIRT2 deacetylase activity.";
RL   Biochem. Biophys. Res. Commun. 437:245-249(2013).
RN   [46]
RP   FUNCTION IN DEACETYLATION OF HISTONE H4K16 AND KMT5A, FUNCTION IN
RP   REGULATION OF KMT5A ACTIVITY; H4K20 METHYLATION; CELL CYCLE
RP   PROGRESSION AND GENOMIC STABILITY, INTERACTION WITH KMT5A, SUBCELLULAR
RP   LOCATION, AND MASS SPECTROMETRY.
RX   PubMed=23468428; DOI=10.1101/gad.211342.112;
RA   Serrano L., Martinez-Redondo P., Marazuela-Duque A., Vazquez B.N.,
RA   Dooley S.J., Voigt P., Beck D.B., Kane-Goldsmith N., Tong Q.,
RA   Rabanal R.M., Fondevila D., Munoz P., Kruger M., Tischfield J.A.,
RA   Vaquero A.;
RT   "The tumor suppressor SirT2 regulates cell cycle progression and
RT   genome stability by modulating the mitotic deposition of H4K20
RT   methylation.";
RL   Genes Dev. 27:639-653(2013).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-368, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   FUNCTION.
RX   PubMed=23932781; DOI=10.1016/j.molcel.2013.07.002;
RA   Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., Xiong Y., Lei Q.Y.;
RT   "Acetylation stabilizes ATP-citrate lyase to promote lipid
RT   biosynthesis and tumor growth.";
RL   Mol. Cell 51:506-518(2013).
RN   [49]
RP   FUNCTION IN DEACETYLATION OF HISTONE H3K18, FUNCTION IN LISTERIA
RP   INFECTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-168.
RX   PubMed=23908241; DOI=10.1126/science.1238858;
RA   Eskandarian H.A., Impens F., Nahori M.A., Soubigou G., Coppee J.Y.,
RA   Cossart P., Hamon M.A.;
RT   "A role for SIRT2-dependent histone H3K18 deacetylation in bacterial
RT   infection.";
RL   Science 341:1238858-1238858(2013).
RN   [50]
RP   FUNCTION IN DEACETYLATION OF G6PD, FUNCTION IN REGULATION OF G6PD
RP   ACTIVITY, INTERACTION WITH G6PD, AND MUTAGENESIS OF ASN-168.
RX   PubMed=24769394; DOI=10.1002/embj.201387224;
RA   Wang Y.P., Zhou L.S., Zhao Y.Z., Wang S.W., Chen L.L., Liu L.X.,
RA   Ling Z.Q., Hu F.J., Sun Y.P., Zhang J.Y., Yang C., Yang Y., Xiong Y.,
RA   Guan K.L., Ye D.;
RT   "Regulation of G6PD acetylation by KAT9/SIRT2 modulates NADPH
RT   homeostasis and cell survival during oxidative stress.";
RL   EMBO J. 33:1304-1320(2014).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25 AND SER-27,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [52]
RP   FUNCTION IN DEACETYLATION OF HIF1A, FUNCTION IN REGULATION OF HIF1A
RP   STABILITY, INTERACTION WITH HIF1A, MUTAGENESIS OF HIS-187, SUBCELLULAR
RP   LOCATION, AND MASS SPECTROMETRY.
RX   PubMed=24681946; DOI=10.1038/onc.2014.76;
RA   Seo K.S., Park J.H., Heo J.Y., Jing K., Han J., Min K.N., Kim C.,
RA   Koh G.Y., Lim K., Kang G.Y., Uee Lee J., Yim Y.H., Shong M.,
RA   Kwak T.H., Kweon G.R.;
RT   "SIRT2 regulates tumour hypoxia response by promoting HIF-1alpha
RT   hydroxylation.";
RL   Oncogene 34:1354-1362(2015).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 34-356 IN COMPLEX WITH ZINC,
RP   AND MUTAGENESIS OF ARG-97; GLN-167; ASN-168; ASP-170 AND HIS-187.
RX   PubMed=11427894; DOI=10.1038/89668;
RA   Finnin M.S., Donigian J.R., Pavletich N.P.;
RT   "Structure of the histone deacetylase SIRT2.";
RL   Nat. Struct. Biol. 8:621-625(2001).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS) OF 34-356 IN COMPLEX WITH NAD
RP   ANALOG AND ZINC.
RX   PubMed=23454361; DOI=10.1016/j.jsb.2013.02.012;
RA   Moniot S., Schutkowski M., Steegborn C.;
RT   "Crystal structure analysis of human Sirt2 and its ADP-ribose
RT   complex.";
RL   J. Struct. Biol. 182:136-143(2013).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 55-356 IN COMPLEX WITH
RP   PEPTIDE INHIBITOR AND ZINC, ENZYME REGULATION, AND MUTAGENESIS OF
RP   GLU-116; GLU-120; PHE-244; GLN-265; SER-271 AND ASP-294.
RX   PubMed=24389023; DOI=10.1016/j.str.2013.12.001;
RA   Yamagata K., Goto Y., Nishimasu H., Morimoto J., Ishitani R.,
RA   Dohmae N., Takeda N., Nagai R., Komuro I., Suga H., Nureki O.;
RT   "Structural basis for potent inhibition of SIRT2 deacetylase by a
RT   macrocyclic peptide inducing dynamic structural change.";
RL   Structure 22:345-352(2014).
CC   -!- FUNCTION: NAD-dependent protein deacetylase, which deacetylates
CC       internal lysines on histone and alpha-tubulin as well as many
CC       other proteins such as key transcription factors. Participates in
CC       the modulation of multiple and diverse biological processes such
CC       as cell cycle control, genomic integrity, microtubule dynamics,
CC       cell differentiation, metabolic networks, and autophagy. Plays a
CC       major role in the control of cell cycle progression and genomic
CC       stability. Functions in the antephase checkpoint preventing
CC       precocious mitotic entry in response to microtubule stress agents,
CC       and hence allowing proper inheritance of chromosomes. Positively
CC       regulates the anaphase promoting complex/cyclosome (APC/C)
CC       ubiquitin ligase complex activity by deacetylating CDC20 and FZR1,
CC       then allowing progression through mitosis. Associates both with
CC       chromatin at transcriptional start sites (TSSs) and enhancers of
CC       active genes. Plays a role in cell cycle and chromatin compaction
CC       through epigenetic modulation of the regulation of histone H4
CC       'Lys-20' methylation (H4K20me1) during early mitosis. Specifically
CC       deacetylates histone H4 at 'Lys-16' (H4K16ac) between the G2/M
CC       transition and metaphase enabling H4K20me1 deposition by KMT5A
CC       leading to ulterior levels of H4K20me2 and H4K20me3 deposition
CC       throughout cell cycle, and mitotic S-phase progression.
CC       Deacetylates KMT5A modulating KMT5A chromatin localization during
CC       the mitotic stress response. Deacetylates also histone H3 at 'Lys-
CC       57' (H3K56ac) during the mitotic G2/M transition. Upon bacterium
CC       Listeria monocytogenes infection, deacetylates 'Lys-18' of histone
CC       H3 in a receptor tyrosine kinase MET- and PI3K/Akt-dependent
CC       manner, thereby inhibiting transcriptional activity and promoting
CC       late stages of listeria infection. During oocyte meiosis
CC       progression, may deacetylate histone H4 at 'Lys-16' (H4K16ac) and
CC       alpha-tubulin, regulating spindle assembly and chromosome
CC       alignment by influencing microtubule dynamics and kinetochore
CC       function. Deacetylates alpha-tubulin at 'Lys-40' and hence
CC       controls neuronal motility, oligodendroglial cell arbor projection
CC       processes and proliferation of non-neuronal cells. Phosphorylation
CC       at Ser-368 by a G1/S-specific cyclin E-CDK2 complex inactivates
CC       SIRT2-mediated alpha-tubulin deacetylation, negatively regulating
CC       cell adhesion, cell migration and neurite outgrowth during
CC       neuronal differentiation. Deacetylates PARD3 and participates in
CC       the regulation of Schwann cell peripheral myelination formation
CC       during early postnatal development and during postinjury
CC       remyelination. Involved in several cellular metabolic pathways.
CC       Plays a role in the regulation of blood glucose homeostasis by
CC       deacetylating and stabilizing phosphoenolpyruvate carboxykinase
CC       PCK1 activity in response to low nutrient availability. Acts as a
CC       key regulator in the pentose phosphate pathway (PPP) by
CC       deacetylating and activating the glucose-6-phosphate G6PD enzyme,
CC       and therefore, stimulates the production of cytosolic NADPH to
CC       counteract oxidative damage. Maintains energy homeostasis in
CC       response to nutrient deprivation as well as energy expenditure by
CC       inhibiting adipogenesis and promoting lipolysis. Attenuates
CC       adipocyte differentiation by deacetylating and promoting FOXO1
CC       interaction to PPARG and subsequent repression of PPARG-dependent
CC       transcriptional activity. Plays a role in the regulation of
CC       lysosome-mediated degradation of protein aggregates by autophagy
CC       in neuronal cells. Deacetylates FOXO1 in response to oxidative
CC       stress or serum deprivation, thereby negatively regulating FOXO1-
CC       mediated autophagy. Deacetylates a broad range of transcription
CC       factors and co-regulators regulating target gene expression.
CC       Deacetylates transcriptional factor FOXO3 stimulating the
CC       ubiquitin ligase SCF(SKP2)-mediated FOXO3 ubiquitination and
CC       degradation. Deacetylates HIF1A and therefore promotes HIF1A
CC       degradation and inhibition of HIF1A transcriptional activity in
CC       tumor cells in response to hypoxia. Deacetylates RELA in the
CC       cytoplasm inhibiting NF-kappaB-dependent transcription activation
CC       upon TNF-alpha stimulation. Inhibits transcriptional activation by
CC       deacetylating p53/TP53 and EP300. Deacetylates also EIF5A.
CC       Functions as a negative regulator on oxidative stress-tolerance in
CC       response to anoxia-reoxygenation conditions. Plays a role as tumor
CC       suppressor.
CC   -!- FUNCTION: Isoform 1: Deacetylates EP300, alpha-tubulin and histone
CC       H3 and H4.
CC   -!- FUNCTION: Isoform 2: Deacetylates EP300, alpha-tubulin and histone
CC       H3 and H4.
CC   -!- FUNCTION: Isoform 5: Lacks deacetylation activity.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + an acetylprotein = nicotinamide + O-
CC       acetyl-ADP-ribose + a protein. {ECO:0000255|PROSITE-
CC       ProRule:PRU00236, ECO:0000269|PubMed:11812793,
CC       ECO:0000269|PubMed:16648462}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- ENZYME REGULATION: Inhibited by Sirtinol, A3 and M15 small
CC       molecules. Inhibited by nicotinamide. Inhibited by a macrocyclic
CC       peptide inhibitor S2iL5. Inhibited by EP300-induced acetylation.
CC       {ECO:0000269|PubMed:18722353, ECO:0000269|PubMed:24389023}.
CC   -!- SUBUNIT: Interacts with CDC20, FOXO3 and FZR1. Associates with
CC       microtubule in primary cortical mature neurons (By similarity).
CC       Homotrimer. Isoform 1 and isoform 2 interact (via both
CC       phosphorylated, unphosphorylated, active or inactive forms) with
CC       HDAC6; the interaction is necessary for the complex to interact
CC       with alpha-tubulin, suggesting that these proteins belong to a
CC       large complex that deacetylates the cytoskeleton. Interacts with
CC       FOXO1; the interaction is disrupted upon serum-starvation or
CC       oxidative stress, leading to increased level of acetylated FOXO1
CC       and induction of autophagy. Interacts with RELA; the interaction
CC       occurs in the cytoplasm and is increased in a TNF-alpha-dependent
CC       manner. Interacts with HOXA10; the interaction is direct.
CC       Interacts with YWHAB and YWHAG; the interactions occur in a AKT-
CC       dependent manner and increase SIRT2-dependent TP53 deacetylation.
CC       Interacts with MAPK1/ERK2 and MAPK3/ERK1; the interactions
CC       increase SIRT2 stability and deacetylation activity. Interacts
CC       (phosphorylated form) with KMT5A isoform 2; the interaction is
CC       direct, stimulates KMT5A-mediated methyltransferase activity on
CC       histone at 'Lys-20' (H4K20me1) and is increased in a H(2)O(2)-
CC       induced oxidative stress-dependent manner. Interacts with G6PD;
CC       the interaction is enhanced by H(2)O(2) treatment. Interacts with
CC       a G1/S-specific cyclin E-CDK2 complex. Interacts with AURKA,
CC       CDK5R1 (p35 form) and CDK5 and HIF1A. Isoform 1, isoform 2 and
CC       isoform 5 interact (via C-terminus region) with EP300.
CC       {ECO:0000250, ECO:0000269|PubMed:11427894,
CC       ECO:0000269|PubMed:12620231, ECO:0000269|PubMed:15213244,
CC       ECO:0000269|PubMed:16648462, ECO:0000269|PubMed:17726514,
CC       ECO:0000269|PubMed:18249187, ECO:0000269|PubMed:18332217,
CC       ECO:0000269|PubMed:18722353, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:21081649, ECO:0000269|PubMed:21949390,
CC       ECO:0000269|PubMed:23454361, ECO:0000269|PubMed:23468428,
CC       ECO:0000269|PubMed:23806683, ECO:0000269|PubMed:24389023,
CC       ECO:0000269|PubMed:24681946, ECO:0000269|PubMed:24769394}.
CC   -!- INTERACTION:
CC       O60566:BUB1B; NbExp=3; IntAct=EBI-477232, EBI-1001438;
CC       O60729:CDC14B; NbExp=2; IntAct=EBI-477232, EBI-970231;
CC       Q12834:CDC20; NbExp=2; IntAct=EBI-5240785, EBI-367462;
CC       Q9UM11:FZR1; NbExp=2; IntAct=EBI-5240785, EBI-724997;
CC       P11413:G6PD; NbExp=3; IntAct=EBI-477232, EBI-4289891;
CC       Q92831:KAT2B; NbExp=4; IntAct=EBI-477232, EBI-477430;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-477232, EBI-73886;
CC       Q9Y572:RIPK3; NbExp=2; IntAct=EBI-477232, EBI-298250;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, perinuclear region.
CC       Cytoplasm. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome,
CC       centriole. Cytoplasm, cytoskeleton, spindle. Midbody. Chromosome.
CC       Perikaryon {ECO:0000250}. Cell projection {ECO:0000250}. Cell
CC       projection, growth cone {ECO:0000250}. Myelin membrane
CC       {ECO:0000250}. Note=Deacetylates FOXO3 in the cytoplasm.
CC       Colocalizes with PLP1 in internodal regions, at paranodal axoglial
CC       junction and Schmidt-Lanterman incisures of myelin sheat.
CC       Colocalizes with CDK5R1 in the perikaryon, neurites and growth
CC       cone of hippocampal neurons. Colocalizes with alpha-tubulin in
CC       neuronal growth cone. Localizes in the cytoplasm and nucleus of
CC       germinal vesicle (GV) stage oocytes. Colocalizes with alpha-
CC       tubulin on the meiotic spindle as the oocytes enter into
CC       metaphase, and also during meiotic anaphase and telophase,
CC       especially with the midbody. Colocalizes with PARD3 in internodal
CC       region of axons. Colocalizes with acetylated alpha-tubulin in cell
CC       projection processes during primary oligodendrocyte precursor
CC       (OLP) differentiation (By similarity). Localizes in the cytoplasm
CC       during most of the cell cycle except in the G2/M transition and
CC       during mitosis, where it is localized in association with
CC       chromatin and induces deacetylation of histone at 'Lys-16'
CC       (H4K16ac). Colocalizes with KMT5A at mitotic foci. Colocalizes
CC       with CDK1 at centrosome during prophase and splindle fibers during
CC       metaphase. Colocalizes with Aurora kinase AURKA at centrosome
CC       during early prophase and in the centrioles and growing mitotic
CC       spindle throughout metaphase. Colocalizes with Aurora kinase AURKB
CC       during cytokinesis with the midbody. Colocalizes with
CC       microtubules. Detected in perinuclear foci that may be aggresomes
CC       containing misfolded, ubiquitinated proteins. Shuttles between the
CC       cytoplasm and the nucleus through the CRM1 export pathway.
CC       Colocalizes with EP300 in the nucleus. Translocates to the nucleus
CC       and chromatin upon bacterium Listeria monocytogenes infection in
CC       interphase cells. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm
CC       {ECO:0000269|PubMed:24177535}. Nucleus
CC       {ECO:0000269|PubMed:24177535}. Note=Predominantly localized in the
CC       cytoplasmic.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
CC       {ECO:0000269|PubMed:24177535}. Nucleus
CC       {ECO:0000269|PubMed:24177535}. Note=Predominantly localized in the
CC       cytoplasmic.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cytoplasm
CC       {ECO:0000269|PubMed:24177535}. Nucleus
CC       {ECO:0000269|PubMed:24177535}. Note=Predominantly localized in the
CC       nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q8IXJ6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IXJ6-2; Sequence=VSP_008724;
CC       Name=3;
CC         IsoId=Q8IXJ6-3; Sequence=VSP_008726;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q8IXJ6-4; Sequence=VSP_008727, VSP_008728;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q8IXJ6-5; Sequence=VSP_055328;
CC         Note=Lacks deacetylase activity, at least toward known SIRT2
CC         targets.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in heart, liver and
CC       skeletal muscle, weakly expressed in the cortex. Isoform 2 is
CC       strongly expressed in the cortex, weakly expressed in heart and
CC       liver. Weakly expressed in several malignancies including breast,
CC       liver, brain, kidney and prostate cancers compared to normal
CC       tissues. Weakly expressed in glioma cell lines compared to normal
CC       brain tissues (at protein level). Widely expressed. Highly
CC       expressed in heart, brain and skeletal muscle, while it is weakly
CC       expressed in placenta and lung. Down-regulated in many gliomas
CC       suggesting that it may act as a tumor suppressor gene in human
CC       gliomas possibly through the regulation of microtubule network.
CC       {ECO:0000269|PubMed:10381378, ECO:0000269|PubMed:10393250,
CC       ECO:0000269|PubMed:12963026, ECO:0000269|PubMed:16909107,
CC       ECO:0000269|PubMed:21791548, ECO:0000269|PubMed:22014574}.
CC   -!- DEVELOPMENTAL STAGE: Peaks during mitosis. After mitosis, it is
CC       probably degraded by the 26S proteasome.
CC       {ECO:0000269|PubMed:12697818}.
CC   -!- INDUCTION: Up-regulated in response to low levels of glucose and
CC       anoxia-reoxygenation stress. Up-regulated by trichostatin A. Down-
CC       regulated in response to high levels of glucose. Down-regulated by
CC       histone deacetylation in several tumors.
CC       {ECO:0000269|PubMed:16909107, ECO:0000269|PubMed:18640115,
CC       ECO:0000269|PubMed:21726808}.
CC   -!- PTM: Phosphorylated at phosphoserine and phosphothreonine.
CC       Phosphorylated at Ser-368 by a mitotic kinase CDK1/cyclin B at the
CC       G2/M transition; phosphorylation regulates the delay in cell-cycle
CC       progression. Phosphorylated at Ser-368 by a mitotic kinase G1/S-
CC       specific cyclin E/Cdk2 complex; phosphorylation inactivates SIRT2-
CC       mediated alpha-tubulin deacetylation and thereby negatively
CC       regulates cell adhesion, cell migration and neurite outgrowth
CC       during neuronal differentiation. Phosphorylated by cyclin A/Cdk2
CC       and p35-Cdk5 complexes and to a lesser extent by the cyclin
CC       D3/Cdk4 and cyclin B/Cdk1, in vitro. Dephosphorylated at Ser-368
CC       by CDC14A and CDC14B around early anaphase.
CC       {ECO:0000269|PubMed:12697818, ECO:0000269|PubMed:17488717,
CC       ECO:0000269|PubMed:17516032, ECO:0000269|PubMed:18332217}.
CC   -!- PTM: Acetylated by EP300; acetylation leads both to the decreased
CC       of SIRT2-mediated alpha-tubulin deacetylase activity and SIRT2-
CC       mediated down-regulation of TP53 transcriptional activity.
CC       {ECO:0000269|PubMed:18722353}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:12697818,
CC       ECO:0000269|PubMed:17516032}.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class I subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD45971.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF67015.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF083107; AAD40850.2; -; mRNA.
DR   EMBL; AF095714; AAD45971.1; ALT_INIT; mRNA.
DR   EMBL; AY030277; AAK51133.1; -; mRNA.
DR   EMBL; KF032391; AGZ02589.1; -; mRNA.
DR   EMBL; AJ505014; CAD43717.1; -; mRNA.
DR   EMBL; AF160214; AAF67015.1; ALT_FRAME; mRNA.
DR   EMBL; AK290716; BAF83405.1; -; mRNA.
DR   EMBL; AK314492; BAG37092.1; -; mRNA.
DR   EMBL; CH471126; EAW56833.1; -; Genomic_DNA.
DR   EMBL; CH471126; EAW56835.1; -; Genomic_DNA.
DR   EMBL; BC003012; AAH03012.1; -; mRNA.
DR   EMBL; BC003547; AAH03547.1; -; mRNA.
DR   EMBL; AF131800; AAD20046.1; -; mRNA.
DR   CCDS; CCDS12523.1; -. [Q8IXJ6-1]
DR   CCDS; CCDS46069.1; -. [Q8IXJ6-2]
DR   RefSeq; NP_001180215.1; NM_001193286.1.
DR   RefSeq; NP_036369.2; NM_012237.3. [Q8IXJ6-1]
DR   RefSeq; NP_085096.1; NM_030593.2. [Q8IXJ6-2]
DR   RefSeq; XP_006723174.1; XM_006723111.1. [Q8IXJ6-2]
DR   RefSeq; XP_011524956.1; XM_011526654.1. [Q8IXJ6-2]
DR   RefSeq; XP_011524957.1; XM_011526655.1. [Q8IXJ6-5]
DR   UniGene; Hs.466693; -.
DR   PDB; 1J8F; X-ray; 1.70 A; A/B/C=34-356.
DR   PDB; 3ZGO; X-ray; 1.63 A; A/B/C=34-356.
DR   PDB; 3ZGV; X-ray; 2.27 A; A/B=34-356.
DR   PDB; 4L3O; X-ray; 2.52 A; A/B/C/D=55-356.
DR   PDB; 4R8M; X-ray; 2.10 A; A/B=38-356.
DR   PDB; 4RMG; X-ray; 1.88 A; A=56-356.
DR   PDB; 4RMH; X-ray; 1.42 A; A=56-356.
DR   PDB; 4RMI; X-ray; 1.45 A; A=56-356.
DR   PDB; 4RMJ; X-ray; 1.87 A; A/B=56-356.
DR   PDB; 4X3O; X-ray; 1.50 A; A=52-355.
DR   PDB; 4X3P; X-ray; 1.80 A; A=52-355.
DR   PDB; 4Y6L; X-ray; 1.60 A; A/B=52-356.
DR   PDB; 4Y6O; X-ray; 1.60 A; A/B=52-356.
DR   PDB; 4Y6Q; X-ray; 1.90 A; A/B/C/D=52-356.
DR   PDB; 5D7O; X-ray; 1.63 A; A/B=50-356.
DR   PDB; 5D7P; X-ray; 1.76 A; A/B=56-356.
DR   PDB; 5D7Q; X-ray; 2.01 A; A/B=56-356.
DR   PDB; 5DY4; X-ray; 1.77 A; A=56-356.
DR   PDB; 5DY5; X-ray; 1.95 A; A=56-356.
DR   PDB; 5FYQ; X-ray; 3.00 A; A/B=1-356.
DR   PDB; 5MAR; X-ray; 1.89 A; A/B=56-356.
DR   PDB; 5MAT; X-ray; 2.07 A; A/C=56-356.
DR   PDBsum; 1J8F; -.
DR   PDBsum; 3ZGO; -.
DR   PDBsum; 3ZGV; -.
DR   PDBsum; 4L3O; -.
DR   PDBsum; 4R8M; -.
DR   PDBsum; 4RMG; -.
DR   PDBsum; 4RMH; -.
DR   PDBsum; 4RMI; -.
DR   PDBsum; 4RMJ; -.
DR   PDBsum; 4X3O; -.
DR   PDBsum; 4X3P; -.
DR   PDBsum; 4Y6L; -.
DR   PDBsum; 4Y6O; -.
DR   PDBsum; 4Y6Q; -.
DR   PDBsum; 5D7O; -.
DR   PDBsum; 5D7P; -.
DR   PDBsum; 5D7Q; -.
DR   PDBsum; 5DY4; -.
DR   PDBsum; 5DY5; -.
DR   PDBsum; 5FYQ; -.
DR   PDBsum; 5MAR; -.
DR   PDBsum; 5MAT; -.
DR   ProteinModelPortal; Q8IXJ6; -.
DR   SMR; Q8IXJ6; -.
DR   BioGrid; 116593; 60.
DR   DIP; DIP-33350N; -.
DR   IntAct; Q8IXJ6; 28.
DR   MINT; MINT-3037896; -.
DR   STRING; 9606.ENSP00000249396; -.
DR   BindingDB; Q8IXJ6; -.
DR   ChEMBL; CHEMBL4462; -.
DR   GuidetoPHARMACOLOGY; 2708; -.
DR   iPTMnet; Q8IXJ6; -.
DR   PhosphoSitePlus; Q8IXJ6; -.
DR   BioMuta; SIRT2; -.
DR   DMDM; 38258608; -.
DR   EPD; Q8IXJ6; -.
DR   MaxQB; Q8IXJ6; -.
DR   PaxDb; Q8IXJ6; -.
DR   PeptideAtlas; Q8IXJ6; -.
DR   PRIDE; Q8IXJ6; -.
DR   DNASU; 22933; -.
DR   Ensembl; ENST00000249396; ENSP00000249396; ENSG00000068903. [Q8IXJ6-1]
DR   Ensembl; ENST00000392081; ENSP00000375931; ENSG00000068903. [Q8IXJ6-2]
DR   Ensembl; ENST00000634533; ENSP00000489602; ENSG00000283100. [Q8IXJ6-1]
DR   Ensembl; ENST00000635478; ENSP00000488940; ENSG00000283100. [Q8IXJ6-2]
DR   GeneID; 22933; -.
DR   KEGG; hsa:22933; -.
DR   UCSC; uc002ojt.3; human. [Q8IXJ6-1]
DR   CTD; 22933; -.
DR   DisGeNET; 22933; -.
DR   GeneCards; SIRT2; -.
DR   HGNC; HGNC:10886; SIRT2.
DR   HPA; CAB004573; -.
DR   HPA; HPA011165; -.
DR   MIM; 604480; gene.
DR   neXtProt; NX_Q8IXJ6; -.
DR   OpenTargets; ENSG00000068903; -.
DR   PharmGKB; PA35786; -.
DR   eggNOG; KOG2682; Eukaryota.
DR   eggNOG; COG0846; LUCA.
DR   GeneTree; ENSGT00870000136486; -.
DR   HOVERGEN; HBG057095; -.
DR   InParanoid; Q8IXJ6; -.
DR   KO; K11412; -.
DR   PhylomeDB; Q8IXJ6; -.
DR   TreeFam; TF106181; -.
DR   SABIO-RK; Q8IXJ6; -.
DR   SIGNOR; Q8IXJ6; -.
DR   ChiTaRS; SIRT2; human.
DR   EvolutionaryTrace; Q8IXJ6; -.
DR   GeneWiki; SIRT2; -.
DR   GenomeRNAi; 22933; -.
DR   PRO; PR:Q8IXJ6; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000068903; -.
DR   CleanEx; HS_SIRT2; -.
DR   ExpressionAtlas; Q8IXJ6; baseline and differential.
DR   Genevisible; Q8IXJ6; HS.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005677; C:chromatin silencing complex; NAS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:GOC.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0097386; C:glial cell projection; ISS:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:UniProtKB-SubCell.
DR   GO; GO:0044224; C:juxtaparanode region of axon; ISS:UniProtKB.
DR   GO; GO:0043219; C:lateral loop; ISS:UniProtKB.
DR   GO; GO:0072687; C:meiotic spindle; ISS:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; ISS:UniProtKB.
DR   GO; GO:0005720; C:nuclear heterochromatin; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0033010; C:paranodal junction; ISS:UniProtKB.
DR   GO; GO:0033270; C:paranode region of axon; ISS:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0048487; F:beta-tubulin binding; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0004407; F:histone deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0070403; F:NAD+ binding; IDA:UniProtKB.
DR   GO; GO:0017136; F:NAD-dependent histone deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0046970; F:NAD-dependent histone deacetylase activity (H4-K16 specific); IDA:UniProtKB.
DR   GO; GO:0034979; F:NAD-dependent protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0033558; F:protein deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0042903; F:tubulin deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0044242; P:cellular lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0061433; P:cellular response to caloric restriction; ISS:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; ISS:UniProtKB.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0071219; P:cellular response to molecule of bacterial origin; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0006342; P:chromatin silencing; NAS:UniProtKB.
DR   GO; GO:0000183; P:chromatin silencing at rDNA; NAS:UniProtKB.
DR   GO; GO:0006348; P:chromatin silencing at telomere; NAS:UniProtKB.
DR   GO; GO:0016458; P:gene silencing; NAS:UniProtKB.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0016575; P:histone deacetylation; IDA:UniProtKB.
DR   GO; GO:0070932; P:histone H3 deacetylation; IMP:UniProtKB.
DR   GO; GO:0070933; P:histone H4 deacetylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:1900425; P:negative regulation of defense response to bacterium; IMP:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:1900226; P:negative regulation of NLRP3 inflammasome complex assembly; IEA:Ensembl.
DR   GO; GO:0070446; P:negative regulation of oligodendrocyte progenitor proliferation; ISS:UniProtKB.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0061428; P:negative regulation of transcription from RNA polymerase II promoter in response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0034983; P:peptidyl-lysine deacetylation; IDA:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0051987; P:positive regulation of attachment of spindle microtubules to kinetochore; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB.
DR   GO; GO:0043388; P:positive regulation of DNA binding; ISS:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; ISS:UniProtKB.
DR   GO; GO:0045836; P:positive regulation of meiotic nuclear division; ISS:UniProtKB.
DR   GO; GO:1900195; P:positive regulation of oocyte maturation; ISS:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:2000777; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0006471; P:protein ADP-ribosylation; NAS:UniProtKB.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0007096; P:regulation of exit from mitosis; NAS:UniProtKB.
DR   GO; GO:0031641; P:regulation of myelination; ISS:UniProtKB.
DR   GO; GO:0042325; P:regulation of phosphorylation; NAS:UniProtKB.
DR   GO; GO:0051775; P:response to redox state; NAS:UniProtKB.
DR   GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0090042; P:tubulin deacetylation; IDA:UniProtKB.
DR   Gene3D; 3.40.50.1220; -; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR017328; Sirtuin_class_I.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   Pfam; PF02146; SIR2; 1.
DR   PIRSF; PIRSF037938; SIR2_euk; 1.
DR   SUPFAM; SSF52467; SSF52467; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Autophagy;
KW   Cell cycle; Cell division; Cell membrane; Cell projection; Chromosome;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Differentiation;
KW   Hydrolase; Immunity; Innate immunity; Meiosis; Membrane;
KW   Metal-binding; Microtubule; Mitosis; NAD; Neurodegeneration;
KW   Neurogenesis; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    389       NAD-dependent protein deacetylase
FT                                sirtuin-2.
FT                                /FTId=PRO_0000110258.
FT   DOMAIN       65    340       Deacetylase sirtuin-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00236}.
FT   NP_BIND      84    104       NAD.
FT   NP_BIND     167    170       NAD.
FT   NP_BIND     261    263       NAD.
FT   NP_BIND     286    288       NAD.
FT   REGION      116    120       Peptide inhibitor binding.
FT   REGION      232    301       Peptide inhibitor binding.
FT   MOTIF        41     51       Nuclear export signal.
FT   ACT_SITE    187    187       Proton acceptor.
FT   METAL       195    195       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236,
FT                                ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:23454361,
FT                                ECO:0000269|PubMed:24389023}.
FT   METAL       200    200       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236,
FT                                ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:23454361,
FT                                ECO:0000269|PubMed:24389023}.
FT   METAL       221    221       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236,
FT                                ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:23454361,
FT                                ECO:0000269|PubMed:24389023}.
FT   METAL       224    224       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00236,
FT                                ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:23454361,
FT                                ECO:0000269|PubMed:24389023}.
FT   BINDING     324    324       NAD; via amide nitrogen.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      23     23       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      53     53       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5RJQ4}.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5RJQ4}.
FT   MOD_RES     207    207       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5RJQ4}.
FT   MOD_RES     368    368       Phosphoserine; by CDK2 and CDK5.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17488717,
FT                                ECO:0000269|PubMed:17516032,
FT                                ECO:0000269|PubMed:18332217}.
FT   MOD_RES     372    372       Phosphoserine.
FT                                {ECO:0000269|PubMed:17516032}.
FT   VAR_SEQ       1     38       MAEPDPSHPLETQAGKVQEAQDSDSDSEGGAAGGEADM ->
FT                                MPLAECPSCRCLSSFRSV (in isoform 3).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_008726.
FT   VAR_SEQ       1     37       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10393250,
FT                                ECO:0000303|PubMed:10931946,
FT                                ECO:0000303|PubMed:12065666,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_008724.
FT   VAR_SEQ       6     76       PSHPLETQAGKVQEAQDSDSDSEGGAAGGEADMDFLRNLFS
FT                                QTLSLGSQKERLLDELTLEGVARYMQSERC -> R (in
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:24177535}.
FT                                /FTId=VSP_055328.
FT   VAR_SEQ     266    271       VQPFAS -> GRGLAG (in isoform 4).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_008727.
FT   VAR_SEQ     272    389       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_008728.
FT   MUTAGEN      53     53       S->A: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN      97     97       R->A: No effect on deacetylase activity.
FT                                {ECO:0000269|PubMed:11427894}.
FT   MUTAGEN      98     98       S->A: Inhibits deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     100    100       S->A: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     116    116       E->A: Reduces binding for the peptide
FT                                inhibitor S2iL5.
FT                                {ECO:0000269|PubMed:24389023}.
FT   MUTAGEN     120    120       E->A: Reduces binding for the peptide
FT                                inhibitor S2iL5.
FT                                {ECO:0000269|PubMed:24389023}.
FT   MUTAGEN     167    167       Q->A: Reduces deacetylase activity.
FT                                Inhibits the block of entry to chromosome
FT                                condensation and subsequent hyperploidy
FT                                cell formation in response to mitotic
FT                                stress; when associated with A-168 and A-
FT                                187. {ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:16909107}.
FT   MUTAGEN     168    168       N->A: Abolishes deacetylation of alpha-
FT                                tubulin. Inhibits deacetylation of
FT                                histone H3 at 'Lys-18'. Inhibits the
FT                                block of entry to chromosome condensation
FT                                and subsequent hyperploidy cell formation
FT                                in response to mitotic stress; when
FT                                associated with A-167 and A-187.
FT                                {ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:12620231,
FT                                ECO:0000269|PubMed:16909107,
FT                                ECO:0000269|PubMed:23908241,
FT                                ECO:0000269|PubMed:24769394}.
FT   MUTAGEN     170    170       D->A,N: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:11427894}.
FT   MUTAGEN     187    187       H->Y,A: Inhibits histone, alpha-tubulin,
FT                                FZR1 and CDC20 deacetylation activities.
FT                                No effect on CDK2-dependent
FT                                phosphorylation. Does not inhibit
FT                                interaction with HDAC6, HIF1A and the
FT                                cyclin E-CDK2 complex. Inhibits
FT                                interaction with KMT5A. Abolishes
FT                                deacetylation, dimeric formation and
FT                                enzymatic activity increase of G6PD.
FT                                Prevents histone H4 methylation at 'Lys-
FT                                20'(H4K20me1) in metaphase chromosomes.
FT                                Inhibits the block of entry to chromosome
FT                                condensation and subsequent hyperploidy
FT                                cell formation in response to mitotic
FT                                stress; when associated with A-167 and A-
FT                                168. {ECO:0000269|PubMed:10381378,
FT                                ECO:0000269|PubMed:11427894,
FT                                ECO:0000269|PubMed:11812793,
FT                                ECO:0000269|PubMed:12620231,
FT                                ECO:0000269|PubMed:12697818,
FT                                ECO:0000269|PubMed:16909107,
FT                                ECO:0000269|PubMed:17488717,
FT                                ECO:0000269|PubMed:17516032,
FT                                ECO:0000269|PubMed:17726514,
FT                                ECO:0000269|PubMed:22014574,
FT                                ECO:0000269|PubMed:24681946}.
FT   MUTAGEN     244    244       F->A: Reduces strongly binding for the
FT                                peptide inhibitor S2iL5.
FT                                {ECO:0000269|PubMed:24389023}.
FT   MUTAGEN     265    265       Q->A: Reduces binding for the peptide
FT                                inhibitor S2iL5.
FT                                {ECO:0000269|PubMed:24389023}.
FT   MUTAGEN     271    271       S->A: Reduces binding for the peptide
FT                                inhibitor S2iL5.
FT                                {ECO:0000269|PubMed:24389023}.
FT   MUTAGEN     279    279       S->A: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     280    280       T->A: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     294    294       D->A: Reduces binding for the peptide
FT                                inhibitor S2iL5.
FT                                {ECO:0000269|PubMed:24389023}.
FT   MUTAGEN     311    311       S->A: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     315    315       Y->A: Reduces deacetylase activity.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     364    364       S->A: Abolishes CDK2-dependent
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:17516032}.
FT   MUTAGEN     368    368       S->A: Does not affect deacetylase
FT                                activity. Abolishes CDK2-dependent
FT                                phosphorylation. Inhibits cellular
FT                                proliferation delay in the early
FT                                metaphase to prevent chromosomal
FT                                instability. Does not inhibit interaction
FT                                with a cyclin E-CDK2 complex. Does not
FT                                inhibit interaction with HDAC6 and
FT                                ubiquitination. Inhibits cell adhesion
FT                                and migration and neurite outgrowth.
FT                                Inhibits deacetylase activity; when
FT                                associated with A-372.
FT                                {ECO:0000269|PubMed:17488717,
FT                                ECO:0000269|PubMed:17516032,
FT                                ECO:0000269|PubMed:18332217}.
FT   MUTAGEN     368    368       S->D: Abolishes CDK2-dependent
FT                                phosphorylation. Inhibits interaction
FT                                with a cyclin E-CDK2 complex. Reduces
FT                                strongly histone deacetylation activity.
FT                                {ECO:0000269|PubMed:17488717,
FT                                ECO:0000269|PubMed:17516032,
FT                                ECO:0000269|PubMed:18332217}.
FT   MUTAGEN     368    368       S->E: Abolishes CDK2-dependent
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:17488717,
FT                                ECO:0000269|PubMed:17516032,
FT                                ECO:0000269|PubMed:18332217}.
FT   MUTAGEN     372    372       S->A: Reduces phosphorylation. Does not
FT                                inhibit interaction with HDAC6,
FT                                ubiquitination and deacetylase activity.
FT                                Inhibits deacetylase activity; when
FT                                associated with A-368.
FT                                {ECO:0000269|PubMed:17516032}.
FT   CONFLICT    199    199       S -> N (in Ref. 6). {ECO:0000305}.
FT   CONFLICT    219    219       P -> L (in Ref. 5; CAD43717).
FT                                {ECO:0000305}.
FT   HELIX        35     45       {ECO:0000244|PDB:3ZGO}.
FT   STRAND       60     63       {ECO:0000244|PDB:4RMH}.
FT   HELIX        64     71       {ECO:0000244|PDB:4RMH}.
FT   STRAND       73     75       {ECO:0000244|PDB:3ZGV}.
FT   STRAND       79     83       {ECO:0000244|PDB:4RMH}.
FT   HELIX        85     87       {ECO:0000244|PDB:4RMH}.
FT   HELIX        89     91       {ECO:0000244|PDB:4RMH}.
FT   STRAND       96     98       {ECO:0000244|PDB:4RMI}.
FT   HELIX        99    101       {ECO:0000244|PDB:4RMH}.
FT   HELIX       103    105       {ECO:0000244|PDB:4X3O}.
FT   HELIX       108    110       {ECO:0000244|PDB:4X3O}.
FT   HELIX       115    119       {ECO:0000244|PDB:4RMH}.
FT   HELIX       121    126       {ECO:0000244|PDB:4RMH}.
FT   HELIX       129    138       {ECO:0000244|PDB:4RMH}.
FT   STRAND      139    142       {ECO:0000244|PDB:3ZGO}.
FT   HELIX       147    157       {ECO:0000244|PDB:4RMH}.
FT   STRAND      161    166       {ECO:0000244|PDB:4RMH}.
FT   HELIX       172    175       {ECO:0000244|PDB:4RMH}.
FT   HELIX       180    182       {ECO:0000244|PDB:4RMH}.
FT   STRAND      183    185       {ECO:0000244|PDB:4RMH}.
FT   STRAND      188    196       {ECO:0000244|PDB:4RMH}.
FT   TURN        198    200       {ECO:0000244|PDB:4RMH}.
FT   STRAND      203    205       {ECO:0000244|PDB:4RMH}.
FT   HELIX       206    215       {ECO:0000244|PDB:4RMH}.
FT   TURN        222    224       {ECO:0000244|PDB:4RMH}.
FT   STRAND      227    232       {ECO:0000244|PDB:4RMH}.
FT   HELIX       241    250       {ECO:0000244|PDB:4RMH}.
FT   TURN        251    253       {ECO:0000244|PDB:4RMI}.
FT   STRAND      255    261       {ECO:0000244|PDB:4RMH}.
FT   HELIX       269    275       {ECO:0000244|PDB:4RMH}.
FT   STRAND      282    288       {ECO:0000244|PDB:4RMH}.
FT   TURN        295    297       {ECO:0000244|PDB:4X3O}.
FT   HELIX       301    303       {ECO:0000244|PDB:5DY4}.
FT   STRAND      309    311       {ECO:0000244|PDB:4RMH}.
FT   STRAND      316    322       {ECO:0000244|PDB:4RMH}.
FT   HELIX       324    334       {ECO:0000244|PDB:4RMH}.
FT   HELIX       338    353       {ECO:0000244|PDB:4RMH}.
SQ   SEQUENCE   389 AA;  43182 MW;  A392442A8F6316F1 CRC64;
     MAEPDPSHPL ETQAGKVQEA QDSDSDSEGG AAGGEADMDF LRNLFSQTLS LGSQKERLLD
     ELTLEGVARY MQSERCRRVI CLVGAGISTS AGIPDFRSPS TGLYDNLEKY HLPYPEAIFE
     ISYFKKHPEP FFALAKELYP GQFKPTICHY FMRLLKDKGL LLRCYTQNID TLERIAGLEQ
     EDLVEAHGTF YTSHCVSASC RHEYPLSWMK EKIFSEVTPK CEDCQSLVKP DIVFFGESLP
     ARFFSCMQSD FLKVDLLLVM GTSLQVQPFA SLISKAPLST PRLLINKEKA GQSDPFLGMI
     MGLGGGMDFD SKKAYRDVAW LGECDQGCLA LAELLGWKKE LEDLVRREHA SIDAQSGAGV
     PNPSTSASPK KSPPPAKDEA RTTEREKPQ
//
